Plain-English, clinically-cited guides to each major psychedelic therapy. What it does, what the evidence actually supports, where the law stands, and how access works in 2026.
Peer-reviewed-cited explainers, medically reviewed by Dr. Michael Teplitsky.
Dissociative anesthetic, FDA-approved (as Spravato) for treatment-resistant depression.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
Classic tryptamine psychedelic; FDA Breakthrough Therapy designation for depression.
US status: Schedule I federally. Legal regulated access in Oregon (Measure 109) and Colorado (Prop 122). Active FDA Phase 3 trials.
Empathogen for PTSD; FDA rejected Lykos's application August 2024, additional Phase 3 required.
US status: Schedule I. FDA rejected first NDA in August 2024; no approved use. Access primarily via clinical trials.
Country-by-country guide to MDMA legality: Australia's prescribing program, decriminalization in Portugal and the Czech Republic, and the US executive order.
US status: Schedule I federally. No state has legalized MDMA. April 2026 executive order directs FDA/DEA to fast-track psychedelic reviews but does not change MDMA's current legal status.
Amazonian N,N-DMT-containing brew; two US religious exemptions, most access abroad.
US status: Schedule I. Legal only via DEA-recognized religious exemption (UDV, Santo Daime, and two newer churches). Retreats otherwise operate abroad.
The 'bufo' / Colorado River toad psychedelic (5-MeO-DMT, aka toad venom) — a short-acting tryptamine; GH Research's GH001 Phase 2b (2025) showed -15.5 MADRS vs placebo in TRD.
US status: Schedule I. Access via international retreats and a small number of FDA-IND clinical trials (GH Research GH001, others).
The two companies racing to turn synthetic 5-MeO-DMT into an approved depression drug — BPL-003 vs GH001 — compared on trial data, delivery, timeline, and market position.
US status: 5-MeO-DMT is Schedule I; neither BPL-003 nor GH001 is FDA-approved. Both hold FDA clearance to run trials (BPL-003 has Breakthrough Therapy Designation for TRD) and are heading toward Phase 3.
The 'God molecule' vs regular DMT — two different tryptamines compared on mechanism (5-HT1A vs 5-HT2A), duration, the type of experience, legal status, and clinical research.
US status: Both 5-MeO-DMT and N,N-DMT are Schedule I federally. N,N-DMT possession is decriminalized in Colorado; neither is FDA-approved, though both have active clinical programs for depression.
A 15-minute synthetic 'white-out' vs a 6-hour Amazonian visionary brew — compared on the molecule, duration, setting, safety, legality, and what each is used for.
US status: Both are Schedule I federally. Ayahuasca has two DEA-recognized religious exemptions; 5-MeO-DMT has none. Access to both is mainly through international retreats or clinical trials.
A 15-minute dose-and-discharge non-dual experience vs a 6-hour psilocybin journey — compared on mechanism, protocol, depression evidence, and access.
US status: Both are Schedule I federally. Psilocybin has regulated legal access in Oregon and Colorado; 5-MeO-DMT does not. Both have active clinical programs for treatment-resistant depression.
The only psychedelic with strong opioid-addiction evidence — and serious cardiac risk. Covers the Texas $50M IMPACT trial and legal retreat options.
US status: Schedule I. No FDA-approved use. Legal access is limited to FDA-IND trials (Texas IMPACT, DemeRx) and international clinics.
Classic long-acting psychedelic; MindMed's MM120 is in Phase 3 for generalized anxiety disorder.
US status: Schedule I. No FDA-approved use. MindMed's MM120 is in Phase 3 (Voyage 1H 2026 readout, Panorama 2H 2026).
N,N-dimethyltryptamine — Schedule I federally; decriminalized in Colorado; the active compound in ayahuasca.
US status: Schedule I. Personal-use possession decriminalized in Colorado (Prop 122). Four religious organizations hold DEA exemptions for ayahuasca use (UDV, Santo Daime, Iowaska, Church of Gaia).
State-by-state and country-by-country guide to DMT legality: Colorado decrim, DEA religious exemptions, and 4-AcO-DMT analogue law.
US status: Schedule I federally. Personal-use possession decriminalized in Colorado (Prop 122). Four religious organizations hold DEA exemptions for ayahuasca use (UDV, Santo Daime, Iowaska, Church of Gaia).
What the April 18, 2026 executive order on psychedelics does — Priority Vouchers, $50M ARPA-H funding, Right to Try, and what it does not do.
US status: Executive order signed April 18, 2026. Directs FDA Priority Vouchers, Right to Try pathway for investigational psychedelics, $50M ARPA-H state-research match, and DEA rescheduling reviews after Phase 3. Does NOT reschedule any psychedelic. All remain Schedule I federally.
Complete list of US cities and counties that decriminalized psilocybin and entheogenic plants — Denver, Oakland, DC, Detroit, Seattle, and 20+ more.
US status: Schedule I federally. City-level deprioritization resolutions do not change state or federal law. They direct local police to treat possession as lowest enforcement priority.
Magic mushroom spores are legal in 46 US states because they contain no psilocybin — illegal in California, Florida, Georgia, and Idaho. Full state-by-state guide.
US status: Spores contain no psilocybin or psilocin and are not federally scheduled. Illegal under state law in California, Florida, Georgia, and Idaho. Germination becomes a federal felony in all 50 states.
4-AcO-DMT (psilacetin) is a psilocybin prodrug not explicitly scheduled — but the Federal Analogue Act treats it as Schedule I when intended for human use.
US status: Not explicitly scheduled federally. Treated as Schedule I under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. Explicitly scheduled in several states including Florida, Georgia, and Louisiana.
State-by-state guide to psilocybin and magic mushroom law in the US — federal status, Oregon, Colorado, and beyond.
US status: Schedule I federally. Legal licensed programs in Oregon (Measure 109) and Colorado (Prop 122). Decriminalized personal possession in Colorado. City deprioritization in 30+ jurisdictions. All other states: illegal.
Which psychedelics are legal in the US in 2026 — ketamine, psilocybin, ayahuasca, and the FDA pipeline.
US status: Ketamine: Schedule III, FDA-approved (Spravato), available nationwide. Psilocybin: Schedule I, legal in OR and CO. Ayahuasca/DMT: Schedule I, religious exemptions only. MDMA, LSD, ibogaine, 5-MeO-DMT: Schedule I, trials only.
Mescaline-containing cactus; federally protected for Native American Church use under AIRFA; slow-growing and in conservation crisis.
US status: Schedule I. Federal exemption under 42 U.S.C. §1996a and 21 CFR 1307.31 for Indians using peyote in bona fide traditional ceremonies. Colorado Prop 122 and Oregon Measure 109 explicitly exclude peyote.
No — kambo is a frog-peptide purge, not a psychedelic. Covers safety risks, the depression question, legal status, and what practitioners won’t tell you.
US status: Not a federally scheduled substance. Practitioners operate outside medical regulation; the FDA has not approved any kambo use. Practices vary by state.
Preparation and post-session work — the 2025 meta-analysis flags preparation hours as the strongest non-drug predictor of outcome.
US status: Not a scheduled substance; widely available through licensed therapists trained via Fluence, CIIS, Naropa, and other accredited programs.
Salvia divinorum is not federally scheduled in the US — but banned in roughly 29 states. It works through kappa opioid receptors, not serotonin, making it pharmacologically distinct from every other psychedelic.
US status: Not federally scheduled (DEA 'drug of concern' designation only). Criminally banned in approximately 29 states. Legal for adults in roughly 15 states. Age-restricted in California, Maine, and Maryland.
A–Z of the words used in psychedelic ceremony, integration, trauma work, and policy — defined in plain English.
US status: Reference page only — not a substance.
Why intention shapes outcome more than dose — plus a 14-prompt worksheet you can print and fill in before your session.
US status: Educational preparation guide — not a substance.
Which medications interact with psychedelics, how long the washout windows are, and the red-flag combinations that send people to the ER.
US status: Safety reference — not a substance and not medical advice.
A 14-day prep timeline covering medication washouts, intention work, body prep, and what to expect on arrival.
US status: Preparation guide — not a substance.
Fight, flight, freeze, and fawn — what each looks like, how triggers map to wounds, and why psychedelics surface them.
US status: Trauma education — not a substance.
The complete printable packing list for an ayahuasca, psilocybin, or 5-MeO-DMT retreat — plus what to leave at home.
US status: Packing reference — not a substance.
Pre-ceremony nutrition, hydration, supplements, sleep, and the foods to cut before a session.
US status: Nutrition and prep guide — not medical advice.
30+ books for psychedelic preparation, integration, trauma, and shadow work — annotated for what each one is for.
US status: Reading list — not a substance.
A printable 30-day journal with one prompt per day for the month after a psychedelic experience.
US status: Journal template — not a substance.
Ketamine is legal nationwide and FDA-approved as esketamine; psilocybin has strong trial data but legal access only in Oregon and Colorado.
US status: Ketamine is Schedule III and legal nationwide (Spravato is FDA-approved); psilocybin is Schedule I federally, with regulated access only in Oregon and Colorado.
How ketamine and SSRIs/SNRIs compare for depression — speed, evidence, cost, side effects, and which to pick when standard pills fail.
US status: Ketamine is Schedule III (legal, prescribed); SSRIs/SNRIs are standard prescription antidepressants.
Two leading options for hard-to-treat depression compared: how they work, FDA status, speed, cost, insurance, and side effects.
US status: Ketamine is a Schedule III controlled substance; esketamine (Spravato) is FDA-approved for treatment-resistant depression. TMS is an FDA-cleared medical device, not a scheduled drug.
Esketamine (Spravato) vs racemic ketamine for depression — FDA status, insurance coverage, cost, setting, and which to pick when.
US status: Spravato (esketamine) is Schedule III and FDA-approved for treatment-resistant depression (standalone use approved January 2025). Racemic ketamine is Schedule III and used off-label for depression, with no FDA approval for that use.
How LSD and psilocybin compare — duration, mechanism, legal access, and clinical trial data for depression and anxiety.
US status: Both LSD and psilocybin are Schedule I federally. Psilocybin has regulated legal access only in Oregon and Colorado; LSD has no regulated legal access anywhere in the US outside clinical trials.
How ibogaine and ketamine compare for addiction — legality, opioid and alcohol evidence, cardiac risk, session length, access, and cost.
US status: Ibogaine: Schedule I, no FDA approval, access only via international clinics or FDA-authorized (IND) trials. Ketamine: Schedule III nationwide, with esketamine (Spravato) FDA-approved for depression.
Two classic serotonergic psychedelics, compared on safety, legality, and the experience — including ayahuasca's serious MAOI drug interaction.
US status: Both Schedule I federally; ayahuasca is legal only via 4 US religious exemptions (most access is at retreats abroad), while psilocybin has regulated legal access in Oregon and Colorado.
Ketamine is legal nationwide and FDA-approved (as Spravato); ayahuasca is Schedule I with legal access limited to four US religious exemptions or retreats abroad.
US status: Ketamine is Schedule III and legal nationwide (Spravato is FDA-approved); ayahuasca is Schedule I federally, with legal access limited to four recognized US religious exemptions.
Ibogaine's strongest evidence is for opioid addiction and carries real cardiac risk; psilocybin's strongest evidence is for depression and anxiety, with regulated access in Oregon and Colorado.
US status: Both Schedule I federally with no FDA approval. Psilocybin has regulated access in Oregon and Colorado; ibogaine requires international travel (Mexico, Portugal, Costa Rica) or an FDA-authorized (IND) trial.
SNRIs, bupropion, and mirtazapine are equally evidence-based first-line options; ketamine (Spravato) is FDA-approved for treatment-resistant depression and psilocybin has positive Phase 3 data.
US status: SNRIs, bupropion, and mirtazapine are standard prescription antidepressants. Ketamine is Schedule III (Spravato FDA-approved). TMS is an FDA-cleared device. Psilocybin is Schedule I federally with regulated access only in Oregon and Colorado.
Both ketamine (Spravato) and TMS are available to veterans through VA health care, but they differ sharply in VA coverage consistency, speed, and PTSD evidence — a veteran-specific breakdown of which to ask for first.
US status: Both are legally available through VA health care. Spravato (esketamine) is Schedule III and FDA-approved for treatment-resistant depression; the VA covers it under the Mission Act at facilities that offer it. TMS is FDA-cleared (not a scheduled drug); many VA medical centers offer it, though availability and coverage details vary by facility.
Buspirone, SSRIs/SNRIs, and CBT are the standard first-line alternatives to benzodiazepines for anxiety; ketamine and psilocybin (MM120, Phase 3 for GAD) are the emerging psychedelic-adjacent options for anxiety that hasn't responded to those.
US status: Buspirone, SSRIs, and SNRIs are standard non-controlled or lower-schedule prescription medications. Ketamine is Schedule III (Spravato FDA-approved for depression, not anxiety). Psilocybin and LSD are Schedule I federally with no FDA approval for anxiety; MindMed's MM120 (LSD) is in Phase 3 trials for GAD.
Psychedelic therapy pairs a controlled psychedelic substance with professional support before, during, and after the session — with evidence strongest for ketamine (FDA-approved as Spravato) and psilocybin (positive Phase 3 trials in 2025).
US status: Ketamine (Schedule III) is legal nationwide; Spravato is FDA-approved. Psilocybin (Schedule I federally) has regulated access only in Oregon and Colorado. MDMA therapy is not FDA-approved.
Becoming a psychedelic therapist requires a clinical license (MD, NP, psychologist, LCSW, or similar) plus specialized training — unless you pursue the Oregon Measure 109 lay-facilitator route, which does not require a clinical license.
US status: Ketamine-assisted therapy is legal nationwide for licensed prescribers. Psilocybin facilitation is legal only in Oregon (Measure 109) and Colorado (Prop 122), each with their own training and approval requirements.
Most psychedelic companies are clinical-stage biotech — pre-revenue, funded by equity raises, and subject to large price swings around FDA decisions and trial readouts. Educational only; not investment advice.
US status: Psychedelic companies operate in a complex regulatory environment — their pipeline drugs range from Schedule III (ketamine) to Schedule I (psilocybin, MDMA). Scheduling status directly affects trial funding and approval timelines.
A curated list of the best psychedelic documentaries — with accuracy notes on where each film's claims align with or get ahead of the clinical evidence.
US status: The substances covered in these films range from FDA-approved (Spravato/ketamine) to Schedule I (psilocybin, MDMA, DMT, ibogaine). Legal access varies widely by drug and state.
Seven ibogaine treatment centers reviewed for cardiac safety protocols, medical credentials, and integration support — all outside the US (ibogaine is Schedule I in the US).
US status: Ibogaine is a Schedule I controlled substance in the US. All centers on this list operate in Mexico, Costa Rica, or Portugal. Legal status in those jurisdictions varies.
Seven vetted ayahuasca retreat centers reviewed for healer lineage, medical screening, integration quality, and safety infrastructure — primarily Peru and Costa Rica.
US status: Ayahuasca contains DMT, a Schedule I substance in the US. All retreat centers on this list operate outside US jurisdiction. Religious use under the Religious Freedom Restoration Act is a separate legal category.
Six at-home ketamine therapy providers compared by dose model, integration support, pricing, and published outcomes data.
US status: All providers listed are legal US telehealth services prescribing compounded ketamine under a valid US prescription. Spravato (esketamine) is separately FDA-approved for in-office administration only.
Six psilocybin retreat centers reviewed across Oregon-licensed service centers, Jamaica, and the Netherlands — licensing, facilitator credentials, integration support, and cost.
US status: Oregon (Measure 109) and Colorado (Prop 122) have licensed psilocybin programs. Psilocybin is Schedule I in all other US states. Jamaica and the Netherlands operate under distinct legal frameworks.
Ketamine therapy options for veterans — VETS grants, VA Spravato coverage, clinic-based infusions, and at-home programs with veteran discounts.
US status: Ketamine is a Schedule III controlled substance in the US. Spravato (esketamine) is FDA-approved for treatment-resistant depression and available at VA facilities. Compounded ketamine is prescribed off-label by licensed telehealth providers.
Where the evidence actually stands for psychedelic-assisted therapy in opioid, alcohol, and nicotine use disorders — with substance-specific deep dives.
US status: Ketamine is Schedule III and legally accessible; psilocybin and ibogaine remain Schedule I federally with no FDA-approved addiction indication. Oregon and Colorado run state psilocybin programs; ibogaine is available only via international clinics and a small number of FDA-IND trials.
What the evidence shows for ibogaine in opioid use disorder — the Texas $50M IMPACT trial, cardiac safety, and how patients taper methadone or suboxone before treatment.
US status: Ibogaine is Schedule I. No FDA-approved indication. Legal access is limited to FDA-IND trials (Texas IMPACT, DemeRx IB-001) and international clinics in Mexico, Costa Rica, and Portugal.
What the evidence shows for ibogaine in alcohol use disorder — smaller than the opioid signal, real cardiac risk, and what to know before booking a clinic.
US status: Ibogaine is Schedule I with no FDA-approved indication. Legal access for alcohol use disorder is limited to international clinics in Mexico, Costa Rica, and Portugal.
What the NYU 2022 JAMA Psychiatry proof-of-concept trial actually showed — 83% reduction in heavy drinking days — and where the research goes from here.
US status: Psilocybin is Schedule I federally with no FDA-approved indication. Oregon (Measure 109) and Colorado (Prop 122) have licensed adult-use programs; clinical-trial access remains the main path for AUD-specific care.
The Johns Hopkins pilot showed 80% biologically-verified smoking abstinence at six months — a stronger outcome than any FDA-approved cessation drug. Here is where the research stands.
US status: Psilocybin is Schedule I federally with no FDA-approved indication. Access for smoking cessation is currently limited to the Johns Hopkins NIDA-funded trial and adjacent research programs.
A single IV infusion typically runs $400–$800, a full 6-session induction $2,400–$6,000, at-home telehealth $129–$350/month, and Spravato $590–$885 per session before coverage. Insurance covers Spravato but rarely off-label ketamine — HSA/FSA generally do.
US status: Off-label ketamine therapy is legal nationwide for licensed prescribers. Spravato (esketamine) is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation, delivered through a REMS network.
Insurance rarely covers off-label ketamine infusion but does cover FDA-approved Spravato — with prior authorization. HSA and FSA funds are generally eligible for medically supervised sessions.
US status: Coverage is a payer question, not a legality question. Off-label ketamine is legal for licensed prescribers regardless of insurance.
Spravato's list price is around $590–$885 per treatment session before insurance. With commercial coverage and Janssen's withMe copay-support program, eligible patients often pay $10 or less per session; Medicare Part B typically covers Spravato after prior authorization.
US status: Spravato is FDA-approved for treatment-resistant depression and for MDD with acute suicidal ideation. It is administered in-clinic only, through the REMS certified-provider network.
At-home telehealth ketamine programs typically run $129–$350 per month for oral or sublingual troches, including provider visits, integration, and dosing. Prices vary widely by session cadence, membership tier, and whether integration therapy is bundled.
US status: At-home oral and sublingual ketamine is legal when prescribed by a licensed clinician. Spravato is never a take-home medication.
Harm reduction is the honest safety layer around psychedelic use — medication interaction screening, drug checking, set and setting, sitters, and integration — for people who will use whether or not there is a legal option.
US status: Harm-reduction information is legal and encouraged. Content is educational only and does not endorse illegal use of controlled substances.
Serotonin syndrome runs from mild (agitation, sweating, tremor) to life-threatening (high fever, seizures, muscle rigidity). Psychedelics that hit 5-HT2A/5-HT1A raise the risk when combined with SSRIs, MAOIs, tramadol, or methylene blue.
US status: Emergency medical information — not a substance and not medical advice. Suspected serotonin syndrome is a 911 call.
In the moment: quiet space, familiar sitter, controlled breathing, no benzodiazepines without a prescriber. The next morning through the next month: sleep, sunlight, therapist, no immediate re-dose. Most difficult experiences integrate — a few need professional care.
US status: Stabilization guidance — educational only, not medical advice. Suicidal ideation, prolonged psychosis, or serotonin-syndrome signs after psychedelic use are 911 or crisis-line calls.
Reagent kits (Marquis, Mecke, Simon's) reveal common adulterants and confirm whether a sample contains MDMA — they do not report purity or dose. Fentanyl test strips are a separate, mandatory second test given ongoing contamination reports.
US status: Reagent test kits are legal to purchase in most US states; possession of an MDMA sample is not. Educational only — the safest option is not to use unregulated substances.
Psychedelic career paths cluster into four tracks: clinical (KAP therapist, psychiatrist), facilitator (Oregon Measure 109, Colorado Prop 122), research (protocol nurse, coordinator, PI), and industry (drug developers, retreat operators). Compensation, credentialing, and legal risk differ sharply across the four.
US status: Career track legality varies: KAP is nationwide, Measure 109 is Oregon-only, Prop 122 is Colorado, MDMA and psilocybin therapy roles outside those states remain in clinical-research settings only.
Most psychedelic research openings are clinical-trial support roles — study coordinator, protocol nurse, data manager, statistician — at MAPS PBC, COMPASS Pathways, Usona Institute, and academic centers like Johns Hopkins, NYU, and UCSF. Prior psychedelic experience is not required.
US status: Research roles operate under FDA-authorized IND studies, so handling Schedule I substances in a trial setting is legal for credentialed staff.
Nurse roles in the psychedelic space fall into two buckets — CRNAs and RNs monitoring ketamine infusions in outpatient clinics, and RNs supporting MDMA or psilocybin trial dosing days. Neither role requires a formal 'psychedelic nurse' credential yet, but KAP training add-ons are the norm.
US status: Nursing roles in ketamine clinics are legal nationwide under standard state scope-of-practice. Trial roles operate under FDA IND authority.
Ketamine-assisted therapy is the one legal psychedelic-therapy track available nationwide. Any licensed clinician (MD, NP, PA, psychologist, LCSW, LPC, MFT) can add KAP through a training program like Polaris Insight, Fluence, or the Ketamine Training Center — typically 40–120 hours, $3,000–$10,000.
US status: Ketamine-assisted therapy is legal in all 50 states under standard off-label prescribing rules. No lay-facilitator pathway exists — KAP requires a clinical license.
Oregon's Measure 109 facilitator license requires 120 hours of core training plus a 40-hour practicum at an OHA-approved program, a background check, and a $2,000 initial license fee. Approved programs run $8,000–$15,000; the whole pathway takes 6–18 months.
US status: Psilocybin facilitation is legal only in Oregon under Measure 109. The certification does not confer legal authority to practice in any other state.
MDMA-assisted therapy training is currently offered through MAPS PBC's Public Benefit training program, Polaris Insight, CIIS's Certificate in Psychedelic-Assisted Therapies, and Fluence's MDMA modules. A clinical license is required — no lay pathway exists. Cohorts are 100–200 hours, $8,000–$14,000.
US status: MDMA is Schedule I with no FDA approval yet. Trained therapists work in clinical-research and sponsor-affiliated settings; off-trial practice remains illegal.
Country-by-country legality of psilocybin, ayahuasca, and MDMA — Netherlands truffles, Portugal and Czech decriminalization, Jamaica and Costa Rica, Brazil and Peru, and Australia's prescribing program.
US status: Not a US-law page — see /guides/what-psychedelics-are-legal-in-the-us for the US-specific breakdown.
What 'legal highs' actually are — unscheduled novel psychoactive substances sold in UK/EU head shops — and why they are not the same as the Schedule I classic psychedelics this site covers.
US status: Not a controlled-substance category — 'legal highs' describes unscheduled novel psychoactive substances, mostly a UK/EU retail term.
What counts as a 'legal drug' — alcohol, caffeine, nicotine, and OTC/Rx medication — and where to find our psychedelic-specific legal-status guides.
US status: Not psychedelic-specific — see /guides/what-psychedelics-are-legal-in-the-us for that coverage.
Amanita muscaria gummies, hemp-derived cannabinoids, and kava — what is actually legal to buy, how it differs from psilocybin, and the real safety risks.
US status: Varies by product and state; none of these products contain psilocybin or another Schedule I psychedelic.
Common short-term effects — dissociation, nausea, blood-pressure changes — plus the long-term bladder risk from frequent, high-dose use.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
A step-by-step walkthrough of a clinical KAP session — screening call, who's in the room, the dosing window, and integration after.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
Ketamine vs electroconvulsive therapy for treatment-resistant depression — evidence strength, cognitive side effects, speed, and cost compared.
US status: Ketamine is a Schedule III controlled substance; esketamine (Spravato) is FDA-approved for treatment-resistant depression. ECT is a regulated medical procedure delivered via FDA-regulated devices, not a scheduled drug.
Medication switching, Spravato/ketamine, ECT, psychotherapy, and trial-stage psilocybin data compared as alternatives to transcranial magnetic stimulation for depression.
US status: Antidepressants and Spravato (esketamine) are FDA-approved prescription medications; ketamine is Schedule III off-label. ECT is an FDA-regulated medical procedure, not a scheduled drug. Psilocybin is Schedule I federally with no FDA approval for depression; access is limited to clinical trials or Oregon/Colorado licensed programs.
Each therapy guide is built from peer-reviewed primary sources — mostly PubMed-indexed trials, FDA advisory committee packets, and state/federal policy documents — not secondary summaries. We link the underlying papers inline so you can verify any claim.
Recent time-sensitive briefings that touch on these therapies, their evidence base, or their legal status.
Study shows electrical stimulation mimics ketamine effects in neurons, suggesting potential non-drug therapies for depression.
Aug 01, 2026
The DEA's extension of Form 222 maintains regulatory oversight of Schedules I and II substances, impacting psychedelic research and industry compliance.
Jul 23, 2026
EPA's proposed SNURs under TSCA may affect the manufacturing and processing of chemicals relevant to psychedelic research, requiring 90-day pre-notification.
Jul 23, 2026
The FDA's strategy on CMC readiness could streamline psychedelic therapy development, addressing unmet medical needs faster.
Jul 23, 2026
A historical review of psycholytic therapy offers insights into early psychedelic-assisted psychotherapy, emphasizing the role of psychedelics as facilitators.
Jul 22, 2026
A study reveals VR's potential in enhancing transformative experiences, suggesting applications in mental health and personal development.
Jul 22, 2026
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.